Log in

NASDAQ:SELBSelecta Biosciences Stock Price, Forecast & News

$2.74
-0.10 (-3.52 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.66
Now: $2.74
$2.85
50-Day Range
$2.51
MA: $3.34
$4.06
52-Week Range
$1.28
Now: $2.74
$4.83
Volume1.85 million shs
Average Volume5.28 million shs
Market Capitalization$239.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Read More
Selecta Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.68 million
Book Value$0.10 per share

Profitability

Net Income$-55,350,000.00

Miscellaneous

Employees39
Market Cap$239.72 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

How has Selecta Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have decreased by 11.3% and is now trading at $2.74. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Selecta Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Selecta Biosciences.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Selecta Biosciences.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences Inc (NASDAQ:SELB) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.07. View Selecta Biosciences' earnings history.

What price target have analysts set for SELB?

7 analysts have issued twelve-month target prices for Selecta Biosciences' shares. Their forecasts range from $4.00 to $13.00. On average, they anticipate Selecta Biosciences' share price to reach $8.17 in the next year. This suggests a possible upside of 198.1% from the stock's current price. View analysts' price targets for Selecta Biosciences.

Has Selecta Biosciences been receiving favorable news coverage?

News coverage about SELB stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Selecta Biosciences earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Selecta Biosciences.

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Novavax (NVAX), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), Agile Therapeutics (AGRX) and Amarin (AMRN).

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:
  • Dr. Carsten Brunn, CEO, Pres & Director (Age 49, Pay $942.52k)
  • Ms. Elona Kogan J.D., Esq., Gen. Counsel & Corp. Sec. (Age 51, Pay $480.77k)
  • Mr. Stephen Smolinski, Chief Commercial Officer (Age 55, Pay $549.39k)
  • Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 32)

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $2.74.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $239.72 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.